drugset / Trial / NCT00044421

Treatment of Peripheral Neuropathy in Patients With Diabetes

NCT00044421 ↗

Phase 3 Completed 400 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this protocol is to determine if an investigational drug is effective in treating nerve malfunction in diabetes.

Timeline

Start
2002-07
Primary completion
—
Completion
2006-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Ruboxistaurin Small molecule — —